Genfit logo

Genfit(OTC) GNFTF

Market Cap$788.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-37%
5 Year+325%
1 Year+323%
1 Month+0%
$15.75
-3.26%
-0.53Today
Genfit last closing stock price
MetricPriceDate
Last closeUSD 15.752026-10-01
Genfit stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 15.752026-08-24
1 month+0%USD 15.752026-08-24
3 month+46.51%USD 10.752026-06-30
Year to date+162.5%USD 6.002025-12-31
1 year+323.39%USD 3.722025-08-06
3 year+314.47%USD 3.802023-09-05
5 year+324.53%USD 3.712021-09-23
Since inception-37%USD 25.002014-01-30

Genfit Financials at a Glance

Market Cap

$788.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€94.28M

Net Income (TTM)

-€140.66M

EPS (TTM)

-$2.39

P/E Ratio

-6.60

Dividend

$0.00

Beta (Volatility)

0.18 (Low)

Price

$15.75

Volume

500

Open

$15.75

Previous Close

$15.75

Daily Range

$15.75 - $15.75

52-Week Range

$3.72 - $16.50

Estimated Earnings Date

Apr 8, 2027

GNFTF News

Human anatomy image with liver highlighted

Better Buy: Intercept Pharmaceuticals vs. Genfit

Keith SpeightsDec 9, 2018
IF_healthcare_10.17.2018_thumb_03

Could a Diagnostic Be Key to Winning This Big Healthcare Market?

Motley Fool StaffOct 19, 2018
MAN IN A TIE DREAMING OF MONEY GettyImages-921609752

Can This Tiny Biotech Revolutionize a $35 Billion Market?

Todd CampbellOct 16, 2018
Human anatomy image with liver highlighted

4 Top Stocks for Investing in Pharma's Next $35 Billion Market

Keith SpeightsApr 8, 2018
Face of scientist in lab with beaker

Should Gilead Sciences Be Worried About Allergan?

Keith SpeightsApr 23, 2017
Scientist at microscope

Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?

Keith SpeightsDec 17, 2016

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genfit

Genfit S.A. is a biopharmaceutical company focused on drug discovery and development for cardiometabolic diseases. The company aims to address high unmet medical needs through innovative treatments for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting the liver.

Products and Services
  • Development of drug candidates for cardiometabolic diseases
  • Focus on early diagnosis and treatment solutions
  • Research in areas with significant unmet medical needs
Growth Outlook
  • Recent quarterly revenue reached €31.93 million, indicating strong market interest
  • Cash and cash equivalents stood at €101.06 million, providing operational stability
  • Research and development expenses reflect commitment to innovation and product pipeline
Financial Highlights
  • Trailing twelve months (TTM) revenue of €142.65 million demonstrates growth potential
  • Net income for the latest quarter was -€75.98 million, highlighting ongoing investment in R&D
  • Current ratio of 1.99 indicates strong liquidity position
Genfit S.A. operates in the biotechnology sector, emphasizing the development of innovative therapies for complex diseases. The company has made significant strides in its research and development efforts, as evidenced by its recent quarterly revenue and cash position. Despite reporting a net loss, the focus on R&D expenses suggests a commitment to advancing its product pipeline, which may lead to future growth opportunities. The current ratio indicates a solid liquidity position, allowing the company to navigate its operational needs effectively. Overall, Genfit S.A. presents a compelling case for potential investors interested in the biotechnology field, particularly in addressing unmet medical needs.
AI Generated • Sep 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

192

CEO

Pascal Prigent

Website

www.genfit.com

Headquarters

Loos, HF 59120, FR

GNFTF Financials

Key Financial Metrics (TTM)

Gross Margin

1.91%

Operating Margin

-130.38%

Net Income Margin

-192.63%

Return on Equity

282.99%

Return on Capital

-46.38%

Return on Assets

-66.51%

Earnings Yield

-15.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$788.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.03M

Volume

500

Avg. Volume

133.359

Financials (TTM)

Gross Profit

€42.87M

Operating Income

-€96.87M

EBITDA

-€41.43M

Operating Cash Flow

€5.16M

Capital Expenditure

-€2.16M

Free Cash Flow

€3.00M

Cash & ST Invst.

€113.65M

Total Debt

€179.01M

Genfit Performance Analysis

Genfit annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 21,224,426-77.6%
20232023-12-31EUR 30,882,06745.5%
20242024-12-31EUR 72,475,444134.7%
20252025-12-31EUR 73,847,3701.9%
Genfit sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-90.3%
Q22025-06-30502.3%
Q42025-12-31-10.1%
Q22026-06-30-34.5%
Genfit annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.50N/A
20232023-12-31EUR -0.6325.2%
20242024-12-31EUR 0.03N/A
20252025-12-31EUR -1.95N/A
Genfit sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-216.0%
Q22025-06-3065.5%
Q42025-12-31-660.0%
Q22026-06-3065.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€20.91M

-65.8%

Gross Profit

€18.84M

-69.2%

Gross Margin

90.09%

N/A

Market Cap

$788.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.89M

N/A

Employees

161

N/A

Net Income

-€25.92M

-185.5%

EBITDA

-€11.17M

-134.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€113.65M

+84.4%

Total Debt

€179.01M

+164.0%

Accounts Receivable

€24.74M

-65.2%

Inventory

€3.99K

-0.1%

Long Term Debt

€113.29M

+89.5%

Short Term Debt

€67.91M

+746.9%

Return on Assets

-66.51%

N/A

Return on Invested Capital

-1.07%

N/A

Free Cash Flow

€2.79M

+123.4%

Operating Cash Flow

€3.33M

+129.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLNCFSilence Therapeutics plc
$4.00+0.00%
SPHDFSanthera Pharmaceuticals Holding AG
$18.30+0.00%
IPHYFInnate Pharma S.A.
$1.65+0.00%
MLLCFMolecular Partners AG
$4.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NKENike
$33.45-4.85%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$28.83-9.23%
NVDANvidia
$236.76+2.56%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.93+10.65%

Questions About GNFTF

What is the current price of Genfit?

Genfit is trading at $15.75 per share.

What is the 52-week range for Genfit?

Over the past 52 weeks, Genfit has traded between $3.72 and $16.50.

How much debt does Genfit have?

As of the most recent reporting period, Genfit reported total debt of €176.97M.

How much cash does Genfit have on hand?

Genfit reported €118.73M in cash and cash equivalents in its most recent financial results.

What is Genfit’s dividend yield?

Genfit does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services